Regulatory Framework and Scientific Approaches for Setting expiry date and Extending Drug Expiry Dates beyond their expiry in India along with guidelines.

Teena S. Bodkhe[1] , Bhagyashri A. Borade [2], Sachin J. Dighade [3]

[1]M. Pharm , Department of Pharmaceutical Quality Assurance, Institute of Pharmacy and Research Badnera Amravati , Maharashtra ,India.

[2]Assistant Professor, Department of Pharmaceutical Quality Assurance, Institute of Pharmacy and Research Badnera Amravati , Maharashtra ,India.

[3]Principal, Institute of Pharmacy and Research Badnera Amravati , Maharashtra ,India.

[1]Corresponding Author: Teena S. Bodkhe

Abstract

Expiry dates are important for drugs, ensuring public health in terms of safety, efficacy, and quality. For India, the legal basis for the establishment of expiry dates is found in the Drugs and Cosmetics Act 1940, accompanied by the Rules of 1945. According to this law, full stability tests at various conditions should be carried out and the shelf life of the drugs determined. However, unique climatic conditions of India, along with constraints on resources and non-cohesive regulatory alignment, make the task challenging. Shelf life can be assessed Carried out by scientific methods, both in real-time and accelerated stability studies, supportive through advanced analysis techniques. Climatic characteristics of Zone IVb need tailor-made Stability protocols are designed to deal with environmental stressors, such as elevated humidity and temperature. Recent research reveals that the effectiveness of some prescriptions may be more prolonged than their Expiration dates, and therefore, there is a possibility for shelf life extension to be based on the right scientific evidence. Such programs are helpful like the USFDA's Shelf-Life Extension Programme (SLEP).Models all over the world for extending shelf lives in emergency or shortage situations. The This same model can be run in India using live data and predictive analytics. analytics, thereby reducing drug wastage and improving access while ensuring patient safety. Collaborative measures would include regulatory bodies, pharmaceutical companies, and research institutions. Institutions would play the key roles in methodology development at the regulatory instances by embracing International standards and conquering the challenges strictly relevant to the Indian Pharmaceutical sector. Future plans will be to target light framework regulations, Advanced Assessment Stability Technologies And Popular Movements Aimed For Public There is consciousness over safety on medicine and sustainable practice toward drug waste.

Key words: Expiration dates of pharmaceuticals, stability assessments, Shelf Life Extension Program (SLEP), reporting obligations to CDSCO, environmental fluctuations, post-market surveillance.

1. INTRODUCTION

The shelf-life of pharmaceuticals is main concerns for patient's safety as well as the effectiveness of the drug. These dates are concerning the period within which a medicine is supposed to be stable under that involves meeting certain prescribed intervals of storagce and pre-set levels of quality, safety and effectiveness [1].Moreover, utilizing medications that have surpassed their expiration dates considerably diminishes their therapeutic efficacy and may induce unpleasant reactions due to chemical degradation products [2]. The inclination to emphasize expiration dates aligns with global practices in pharmacovigilance. The focus of their work is to raise and improve the quality of the public health with the purpose of providing better living environment. These moves and approvals of the extension of pharmaceutical expiration dates are made strategic procedures, which entail the understanding of scientific and legal requirements. Therefore, as a requirement for shelf life evaluation where required by the stability studies for the product under many circumstances, the regulators safeguard the interest of all people no matter their race. Assessing how long a product will remain stable once stability is achieved and tested at a faster rate is a challenging process; homogenizing batches is impossible [3].

India has few more challenges such as lack of fund, problem associated with integration of rules and regulation, and science knowledge in conducting stability studies. Some scientific challenges are formulation of drug, variations in the environment, absence of good models that can be used to extend the shelf life [4]. Through priorities established in cooperation between the regulators, manufacturers and scientists, these challenges will be overcome. This research will review medicine expiry dates under the emerging economic laws of India against the USFDA and EMA entities. The exposition will be devoted to shelf-life evaluation and shelf-life enrichment techniques as well as scientific methods in connection with pharmaceuticals in the sight of their impact for improvement of health care system on the Indian subcontinent. Finally, to improve the availability of effective drugs, the evaluation will make suggestions for the convergence of India's legislation and scientific techniques presented in this evaluation to international norms [5].

2. REGULATORY FRAMEWORK ON SETTING EXPIRY DATES

2.1 Indian Regulations Provisions

The Indian legal environment for the development of the pharmaceutical industry is carried out according to the Drugs and Cosmetics Act of 1940, with amendments, and the rules associated with it from 1945, the global legal environment for the development of the pharmaceutical industry is based on both local and international legislation. These regulations apply to manufacturing, availability, promotion and packaging of pharmaceutical products in the market With proper storage, these pharmaceutical products are adequately preserved at the time of expiry of their shelf life. For the purpose of the law, it is necessary after stability studies carried out under set conditions to set a maker expiration date. These tests make it possible that if properly stored and used, the medicine should be expected to have the quality, purity and potency. In addition to this, the picked Section IX of The Drugs and Cosmetics Rules, 1945 elucidates labeling, storage and stability testing as the method of calculating the expiration shelf life of various available medical drug formulation in market such as the five mentioned above.The Act mandates the implementation of evaluation methods that must integrate accelerated stability testing for the determination of shelf life and extended stability, yielding more definitive data on the degradation mechanisms occurring under standard storage conditions [6].Rule 96 of the Drugs and Cosmetics Rules, 1945, stipulates that every drug must contain existing labeling rules are explicit, requiring that both manufacturing and expiry dates be clearly distinguished on each container. Expiration dates should be easy to read in terms of the month and year and clearly visible to the public as well as healthcare providers [7]. Moreover, such provisions are along international best practices supporting consumer safety and informed use. For short shelf-life products, such as reconstituted antibiotics, the expiry date must be data based specific to climatic zones of India with suitable temperature- and humidity-specific conditions [8].

It forms the basis of the scientific and regulatory protocols followed within Indian drug regulatory frameworks to ensure safe, good, and effective pharmaceutical products. Its basic component is stability testing: the study of shelf lives based on testing against various environmental conditions. The ICH guidelines that include Q1A (Stability Testing), Q1B (Photostability Testing), Q1C (New Dosage Forms), Q1D (Bracketing and Matrixing Designs), and Q1E (Evaluation of Stability Data) set international standards for the formulation and evaluation of stability studies. These worldwide standards are followed by India to ensure

uniformity in regulation and to support international trade opportunities [9]. Furthermore, recommendations made by the World Health Organization underscore the importance of carrying out stability testing in climatic zones, particularly zones III and IV that relate to India.

Such harmonization would help in making ensure that regulation is aligned with the International norms of such a recommendation and for providing for extension of dates from a scientific data based prospective of the Indian regulation. However, local operation complexities are still an issue as supported by India where legal changes dictate the impact analysis of drug stability and safety to the patient [10].The CDSCO holds the very important position in the procedure regarding expiration dates and extension. Manufacturers are required by CDSCO to submit stability data encompassing accelerated and long term studies of stability before expiry dates can be assigned to these drugs. In the process of expiration date extension, it expects evidence of a stability profile that is constant during extended stability studies; it cannot compromise the use in quality and safety in drugs and patients. Furthermore, the responsibilities of the CDSCO include the authorization of modifications to the shelf life of repurposed medications or in response to public health crises, exemplified by the COVID-19 pandemic when regulatory procedures were expedited to facilitate faster approvals for repurposed treatments [11]. This has guaranteed that the regulatory level is tightly attuned to this necessity, affecting the observed absorptive capacity. highlights the CDSCO's dedication to harmonizing public health priorities with pharmaceutical regulation.

3. SCIENTIFIC APPROACHES TO SETTING EXPIRY DATES

3.1 Stability Testing

Real-time Stability Studies: These investigations assess the drug's performance under standard storage circumstances stability under situations that would not have been otherwise evaluated throughout its shelf life, therefore providing a direct indication of its shelf life efficacy [12].

Accelerated Stability Studies: The experiments were carried out at higher temperature and humidity to evaluate the effect of long term exposure over a short time period on the stability of the drug [13].

Analyzed Parameters

Potency: The extent to which the medicine can deliver the therapeutic effect within the body systems that must stay constant within set values in specific periods up to the shelf life of the drug [14].

Degradation Products: pinpointing as well as measuring of second metabolites likely to occur at some point during shelf-life of the commodity affecting its safety and performance [15].

Physical Stability: Analytical methods such as chromatographic and spectroscopic used to determine the changes in the color, solubility and other characteristics which seem to reveal degradation [16]. These scientific methodologies are beneficial in defining drug safety; however, the controversy emerges in extending the expiry dates through simulation and state-of-the-art risk assessment, not empirical testing.

3.2 Climatic Considerations in Stability Studies

The procedures used in the legal and political systems regulating medicine expiry in India is pegged on scientific principles ranging from climate. Pharmaceutical stability testing facilitates the identification of the products shelf life especially for India coming under Zone IVb which includes high heat and humidity. They determine how constant a drugs chemical, physical and microbiological properties are to guarantee that the product formulated as the expiry date is still efficacious [17].

Details of Zone IVb: Evaluation of the preferences of Zone IVb, in terms of humidity and temperature, have made it possible to check for other factors which may enhance drug stability and ensure they are effective in their functioning.

Thermal-Cycling Stress Studies: These evaluate the solidity of a drug and effect of temperature fluctuations it undergoes in conditions that mimic severe transport temperatures.

Regulatory recommendations: Some recommendation that concerns the ICH and the WHO should be implemented when conducting stability tests with a view of preserving the efficiency of the medication in question under the different set conditions [18].

Consequences of Prolonged Expiration Dates

Post-Expiry Efficacy: Studies show that an overwhelming percentage of the pain relievers sold in pharmacies still contain their product usability, effectiveness and safety for as much as two years past the expiration date, a fact that implies that expiration rules may not reflect the

reality in terms of the shelf life of these products [19].The constant analysis on regulations regarding stability studies has subsequently created strict reportage and filing system. testing methodologies; thereby making medication safety and efficacy evaluative procedures more secure [20]. Therefore, notwithstanding all the advantages connected with the possible stockpiling of drugs and other aspects of efficiency, it arouses concerns relating to patients' safety and the possible decrease in medication's effectiveness. The comparison the evidences of the analysis reveal permanent curative efficacy concerning sibutramine. These elements must be has been thoroughly examined by the regulatory bodies of India.

Case Analyses

Analgesic Agents: Studies on commonly used analgesics such as Ibuprofen and Diclofenac showed that these drugs were fully chemically stable and pharmacologically active even after two years past their stated expiration date suggesting that the presently provided dates of expiration are not particularly accurate regarding the real shelf life of the drugs [21].

Stability Under Indian Conditions: According to scientific literature, studies have found that local environmental conditions affecting drug stability hence the need to do specific stability studies to guarantee drug safety and efficacy in the Indian environment [22]. Although scientific evidence-based extension of expiry dates may be helpful in enhancing drug availability, it may raise some concerns regarding potential risks arising from drug degradation and thus stringent regulatory scrutiny to protect the patient.

4. EXTENSION OF PHARMACEUTICALS PAST THEIR LABELED EXPIRATION DATE

4.1 Regulatory Considerations

Extended Expiry Date Approval Process: This includes an extended comprehensive regulatory framework in India based on the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. In such cases, manufacturers need to file stability data in compliance with ICH guidelines to prove that a drug is safe, efficacious, and of quality after the labeled expiry date. The CDSCO evaluates this information before giving permission for extension [23]. A detailed assessment ensures that factors like storage conditions and the integrity of packaging are taken into account in the decision-making process.

Extraordinary circumstances in which extensions are issued: Extensions are awarded in extraordinary circumstances. It includes public health emergencies and shortages of drugs. For

example, during the COVID-19 pandemic, regulatory bodies from all over the world-including India-were required to temporarily extend shelf lives of certain critical drugs as a measure to prevent a shortage. These were mainly based on data given by manufacturers or emergency stability studies provided by government agencies [24,25]. The WHO also has guidelines for managing such emergencies, with an emphasis on the need for rapid, yet scientifically sound, assessments to protect patients [26]. In this regard, the role of CDSCO in making sure that India adheres to international standards in this regard is reflective of best practices worldwide.

4.2 Scientific Methodologies

The scientific basis for the extension of drug expiry dates in India, as encapsulated within the current regulatory regime, is the central focus of this study. procedures that define whether a drug will be safe and effective or not. These methods of shelf life extension may include other Type 1 studies and practice: more stability analyses, RT use and RT-derived data, and comparison with There are standards like the FDA's Shelf Life Extension Program exist internationally.

Secondary Stability Check for Shelf Life: Overall stability of these products under various conditions gives important information on the robustness of the pharmaceutical products. One study demonstrated that some encapsulated formulations with doxorubicin were stable for prolonged periods in controlled environments [27].

Use of real-time and historical data: With history-based drug performance data, extension decisions about expiry dates can be well-made. This would go well with food labeling where the study of the behavior of consumers and how the products perform over time is considered important [28].

Comparison with International Practices: The Shelf Life Extension Program implemented by the FDA acts as an ideal benchmark that helps in the date extension of expiration through the empirical data. Such an approach shall assist Indian regulatory authorities by developing comprehensive regulations for date extension, thus protecting human health and reducing waste also [29]. Although this action would proposed to maximize resource utilization, it has to base on sound safety assessment to minimize potential health impacts when medicines that have gone out of date are given.

4.3 Ethical and Safety Concerns

Such measures as the extension of expiry dates of Pharmaceuticals guarantees appropriate safety as well as efficacy of the drugs even safely after the fixed expiry times especially given the resources constraints in settings such a India. Prolonging the expiry date of drugs requires rigorous scientific verification through stability studies, which ensure that degradation is not detrimental to potency and does not form harmful by-products. The Drugs and Cosmetics Act of 1940 requires scientific evidence-based shelf life determination for Ayurvedic and allopathic drugs; the importance of real-time stability studies has to be assured for safety [30]. Homeopathic drugs are usually assigned shorter regulatory shelf lives although studies show that they remain effective for more than 25 years, indicating a need for harmonized regulatory frameworks based on strong scientific evidence. Issues on degradation would be addressed through the standardization of chemical assay protocols for monitoring API stability with time. Ethically, the health care systems should ensure that extended-use drugs are just as safe as newly manufactured ones to instill public trust and reduce the risks of loss of therapeutic effects [31]. The drug expiry date is given as well as renewed by such prescription in India within an international or organizations' guidelines such as ICH and WHO. These ensure that all pharmaceuticals are safe, effective as well as of quality throughout the shelf life. The rest segments deal with the guidelines which are to be followed by the industries and the procedure relating to stability studies

5. GUIDELINES FOR INDUSTRY COMPLIANCE

Section	Details	References
Regulatory Framework	Guidelines from ICH, WHO, and national regulations ensure drug safety, efficacy, and quality.	**[31]**
Industry Compliance		
Regulatory Bodies	Indian Pharmacopoeia Commission oversees manufacturer compliance with standards.	[32]

Expiry Date Regulations	Manufacturers must display expiry dates; drugs may lose efficacy post-expiry.	[33]
Stability Studies		
ICH and WHO Frameworks	Comprehensive stability testing guidelines to determine expiry dates.	[34]
Recommended Protocols		
Accelerated Stability Assessment Procedure (ASAP)	Statistical tools predict shelf life more quickly.	[35]
Temperature Cycling Studies	Assess stability under varying temperatures to ensure quality during transport/storage.	[36]

Table no.1. Regulatory Framework and Stability Guidelines for Drug Expiry in India"

5.1 Reporting and Documentation

Requirements for the Submission of Stability Data to CDSCO: To find out the expiry dates, the pharmaceutical companies need to submit stability data to the CDSCO. This stability data embraces the stability of the drug in different environmental conditions and is the part of the shelf life assessment [37]. Significance of Comprehensiveness and Comprehensive: Provision of detailed particulars of information for stability is essential so as to gain clientele confidence and instill confidence in patients on safety. A clear application of information avoids miscarriage on issues about drug registration and date of the extended period [38]. There is another opinion that high standards are a barrier to innovation and delay the availability of drugs most needed. The pharmaceutical industry still faces the challenge of timely availability of drugs and compliance with regulations [39].

6. OBSTACLES & IMPEDIMENTS

6.1 Environmental Variation

Climatic Zones: India undergoes variabilities in climatic conditions that may affect the stability of the drugs. For for example, high temperature and humidity affect the rate of degradation and so some areas need more rigid ones expiry controls.

Storage Conditions: There is also tendency that due to the improper storage under the best-known conditions, their effect may be weakened. recommended conditions. According to the guidelines of International Conference on Harmonization (ICH), some storage conditions may not be appropriate in different Indian climatic conditions [40].

6.2 Regulatory Barriers:

Lack of Standardization: Differences in standardized procedures for settling the shelf lives within different climatic regions complicate the adherence by the regulations [41]. Professional judgment often depends on pharmacists in order to extend beyond-use dates, which may at times result in variations in practice [42].

6.3 Methodological frameworks

Stability Study: Thorough stability study is part of the process that ensures reliable dates of expiry. This includes chemical stability testing of active ingredients under different conditions [43].

Inventory Management: Best inventory management practices such as FIFO and LIFO help diminish problems associated with the expiration of drugs [44].

6.4. Resource Limitations Confronting Smaller Producers

Economic Constraints: Micro-scale manufacturers usually have fewer monetary resources that can be directed towards wide-ranging stability testing; this is one of the factors determining and also extends shelf life [45].

Access to Technological Resources: Many small businesses lack access to advanced analytical technologies, which are necessary for carrying out stability studies, and this prevents them from accurately establishing expiration dates [46].

Regulatory Compliance: The sheer intricacy of regulatory demands may form an obstacle for small scale ventures as it might be arduous to meet expectations laid down by CDSCO [47].

6.5 Implication of Resource Constraints

Market Competition: Such constraints may lead to reduced market competitiveness. More resourceful larger firms are better positioned to handle regulatory challenges [48].

Risks to Patient Safety: Inadequate stability assessments can lead to the dissemination of pharmaceuticals that may be ineffective or possibly dangerous, thereby affecting patient safety [49].

6.6 Gaps in Public Awareness

Lack of knowledge Most people do not know what an expiration date actually means, and thus believe most medication to be safe forever [50].

Accessibility of Information: Much information on the expiry date is written in small legibility on packaging and the consumer is unable to read it.

Technological Solutions: Although there is a suggestion to use applications to track expiration dates, their use has been limited, which reflects a lack of public engagement with technology [51].

6.7 Regulatory Considerations

Regulatory Control: The Central Drug Controller and State Drug Control Administration take care of monitoring compliance, but official ignorance is what defeats that effort [52] .The need for educational projects is apparent, as a pressing need to create mass awareness about the significance of dates of expiration of drugs and danger associated with the consumption of aged drugs [53] arises. However, a few argue that an focus on dates of expiration would divert attention from other critical matters related to drug safety, and that proper storage and handling will also play a significant role to maintain the efficacy and potency of drugs.

7. FUTURE DIRECTIONS

The following new and advanced approaches for stability testing include forced degradation analytical techniques and other complex stability testing techniques. paradigms, is essential for improving the accuracy of estimates of shelf life, as well as for other functions, using analytical methods [54]. There thus there is need for a daily interaction between the industry professionals and the regulatory authorities on the issue. combine and optimize the stability testing standards in order to conform to the scientific and the regulatory nurse. requirements [55].

Advancement of Flexible Structures of Regulation: The regulatory structure monitoring drug expiration dates in India has changed with time. It is driven by scientific research, consumer safety, and standardization efforts for the whole world. However, considering the fast pace of pharmaceutical innovations and healthcare requirements, there is a pressing need for more elastic and responsive frameworks that answer both the current and the future problems.

Integration of Real-Time Stability Data: The real-time monitoring of stability should involve including various technologies in regulatory agencies such that better expiration dates may be generated. Digital tools, namely predictive analytics and algorithms developed for machine learning, shall help replicate long-term stability, thus reducing dependency from conventional shelf-life estimates. These, in addition, shall facilitate continuous information about a product's stability in different storages.

Scientific Innovations toward Stability Extensions: Drug expiry extension protocols would need evidence-based approaches. Recent scientific strides with accelerated stability testing and studies of molecular degradation may afford an opportunity for safe extensions of shelf life. In these frameworks, dynamic reassessment of expiry dates can become a reality [56].

Global Harmonization Coupled with Local Adaptation: The pursuit of alignment with international standards, including the ICH Q1A (R2) concerning stability testing, should occur concurrently with adjustments tailored to India's distinctive pharmaceutical environment. By integrating globally recognized practices while also considering local climatic factors, supply chain obstacles, and market needs, enhancements in regulatory adherence and medication safety may be achieved [57].

Post-market surveillance systems: India needs better post-market surveillance systems that will monitor the performance and safety of drugs near or past their expiration dates. It will also furnish real world data for decisions on the extension of shelf-life and conditional uses approvals [58].

Environmental and Economic Impact: Moreover, higher level implications of drug expiration, must necessarily be reflected in adaptive frameworks. Reducing pharmaceutical waste by optimised expiry extensions established based on scientific evidence, might be effective in both environmental and economical contexts.

For instance, fewer disposed drugs reduce environmental pollution; longer usability might reduce its cost and enhance accessibility [59].

Improved Cooperation Among Stakeholders: The improvement of the regulatory strategies would require more cooperation between CDSCO, pharmaceutical firms, and research institutions. Cooperative efforts ensure that extensions of expiration dates are scientifically proven, widely accepted, and properly implemented [60].

Revised Guidelines and Public Communication: The guidelines should also address issues related with communicating with the HCPs and the general public. Dispelling the myths pertaining to the ef cacit of expier drugs and inventory, management and education crusades should go hand in hand Clear labeling and education as well as increased cross selling by governments and private institutions to share information is important. The structure of regulation in India is defined by both another piece of legislation, namely the Drugs and Cosmetics Act of 1940, and comprehensive stability testing, along with expiration dates for formulated products for pharmaceuticals. However, there are still significant gaps that include practices inadequate to international standards, optimal resource utilization, and extension of drug expiry periods for actual application [61].

Current Issues: Expiry dates are overestimated primarily due to the lack of stability information and varied storage conditions [62] . The pharmaceutical industry in India suffers tremendous financial losses due to wastage of expired drugs, which are generally stored with a potency of 90% [63].

Importance of Public-Private Data Sharing Increased collaboration between the public and private sectors can drive the following benefits:

Data Pooling: Aggregation of real-world data from common databases shared between hospitals and manufacturers will improve the stability testing preciseness.

Cost Efficiency: Money in terms of reducing wastage by extending shelf life, especially during drug shortages.

Regulatory Innovation: Sharing data through collaborative platforms empowers Indian regulatory agencies to put in place structures like that of the U.S. FDA's Shelf-Life Extension Program (SLEP), which has proven pharmaceuticals to last much beyond their expiration dates [64].

CONCLUSION

The regulatory framework as well as scientific approaches set and extend drug expiry dates in India based on an assurance of drug safety and efficacy and public health. The Drug and Cosmetic Act of 1940 for India is consistent with ICH and WHO; therefore, commenced with stability testing for the determination of shelf life of drugs. However, other challenges result mainly from environmental fluctuations, limited available capital for such small-scale producers, and from the general ignorance of the public on the importance of medicine expiration dates.

Real time and accelerated stability studies are potential approaches for determining shelf life; but presence of climate change in India and lack of standard protocols necessitates improvement in these techniques. The opportunity to increase shelf-life, especially when used in critical cases, complements the existing approaches to the optimal management of safety and supply. From the literature, it is clear that the majority of the drugs remains effective for far much longer than the dates of expiration, several factors make it imperative to seek conclusive analytical, experimental, safety, efficacy and legal scrutiny on the degradation products. To resolve these challenges, five strategies namely Adaptive Regulatory Frameworks, Collaboration and Data Sharing, Public Awareness and Communication are rolled out. The next research agenda must address the concerns that include: adoption of new scientific approaches, strengthening of regulations and improved cooperation of all stakeholders to ensure the availability of safe, effective and affordable drugs. Thus, the regulation that complies with the Indian conditions by following the generally accepted standards can easily adapt to counteract the new difficulties of the pharma industry and minimize the costs and the adverse impact on the environment brought by the excessive amounts of pharmaceuticals waste.

REFERENCE

1. World Health Organization. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. WHO Technical report series. 2009;953:87-123.
2. Sengupta P, Chatterjee B, Tekade RK. Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: A comprehensive review. International journal of pharmaceutics. 2018 May 30;543(1-2):328-44.
3. Guideline IH. Stability testing of new drug substances and products. Q1A (R2), current step. 2003 Feb;4(1-24).

4. Bansal G, Suthar N, Kaur J, Jain A. Stability testing of herbal drugs: Challenges, regulatory compliance and perspectives. Phytotherapy Research. 2016 Jul;30(7):1046-58.
5. Vivekanandan K, Prakash J, Muthusamy K, Singh GN. Quality standards and current status of ophthalmic formulations in Indian Pharmacopoeia and National Formulary of India. Therapeutic Innovation & Regulatory Science. 2014 May;48(3):386-92.
6. Kavya HS. Regulatory Provisions for Cosmetics in India. Research Journal of Topical and Cosmetic Sciences. 2022;13(1):14-20.
7. Jadaun GP, Kalaivani M, Kumar M, Singh GN, Raghuvanshi RS, Jain P, of the Study P. Report of a collaborative study to establish the first Indian Pharmacopoeia reference standard for teriparatide. Biologicals. 2024 May 1;86:101755.
8. Agarwal DS, Chairman DT. Central drugs standard control organization. 2017.
9. Yadav AM, Murthy MS, Shete AS, Sakhare S. Stability aspects of liposomes. Indian journal of pharmaceutical education and research. 2011 Oct 1;45(4):402-13.
10. Shantanu K, Bhagwat P. New Clinical Trials Regulations-2013 in India & its Possible Impact on Indian Clinical Trials Framework. Indian Journal of Pharmacy Practice. 2013;6(4).
11. Deeksha KS, Balamuralidhara V, Gowthami KR, Thoyajaksha V, Thanush D. India's Regulatory Frames for Adoption of Repurposed Drugs as Covid-19 Treatment: A Recent Study Approach.
12. Солдатов АА, Яковлев АК, Авдеева ЖИ, Горенков ДВ, Коровкин АС, Косенко ВВ. Обзор современных регуляторных требований к изучению стабильности биологических лекарственных препаратов. БИОпрепараты. Профилактика, диагностика, лечение. 2024;24(3):335-47.
13. Lennard A, Zimmermann B, Clenet D, Molony M, Tami C, Aviles CO, Moran A, Pue-Gilchrist P. Stability Modeling Methodologies to Enable Earlier Patient Access. Journal of Pharmaceutical Sciences. 2024 Sep 27.
14. Miss, Ashu., K., Tanuj, Sapra. Chemical stability of drugs. (2023).178-187. doi: 10.58532/v2bs23p1ch15
15. Vyas AJ, Jadav CD, Patel AI, Patel AB, Shah SR, Sheth D, Dholakia S. Review on Stability Indicating Assay Method or Forced Degradation Study: Strategy and Regulatory Consideration. Asian Journal of Pharmaceutical Analysis. 2023;13(2):131-9.
16. Subhramanya AB, Nayak P, Ramalingappa H, Hemanna HK, Shetty P. ICH Q1 a Stability Testing for New Dosage Form. International Journal of Pharmaceutical Investigation. 2024 Jul 1;14(3).

17. Haider K, Akash MS, Faheem A, Rehman K. Guidelines for drug stability and stability testing. Drug Stability and Chemical Kinetics. 2020:19-29.
18. Kamran, Haider., Muhammad, Sajid, Hamid, Akash., Amna, Faheem., Kanwal, Rehman. Guidelines for Drug Stability and Stability Testing. (2020).19-29. doi: 10.1007/978-981-15-6426-0_2
19. Sharma S, Sharma AK, Moe HW, Khanapure A, Mohan P. A study to investigate the chemical potency, physical stability, and efficacy of analgesic agents over a period of two years post their expiry date. medical journal armed forces india. 2022 Sep 1;78:S194-200.
20. Facci J, Diniz LF, Reis NF, Fernandes C. Evolution of legislation and analytical techniques applied to stability studies for active ingredients and pharmaceutical products. Química Nova. 2020 Aug 21;43:959-73.
21. Sharma S, Sharma AK, Moe HW, Khanapure A, Mohan P. A study to investigate the chemical potency, physical stability, and efficacy of analgesic agents over a period of two years post their expiry date. medical journal armed forces india. 2022 Sep 1;78:S194-200.
22. Alekhacharan S, Raul SK, Padhy GK. Stability Development Strategies and Impurities Profile Consideration in Pharmaceuticals: A Review.
23. Drugs and Cosmetics Act, 1940, and Rules, 1945. Ministry of Health and Family Welfare, Government of India. https://cdsco.gov.in
24. Stability Testing of New Drug Substances and Products Q1A(R2). International Council for Harmonisation. https://www.ich.org
25. Thenge R, Adhao V, Mehetre G, Chopade N, Chinchole P, Popat R, Darakhe R, Deshmukh P, Tekade N, Mohite B, Kayande N. Modification of physicochemical properties of active pharmaceutical ingredient by pharmaceutical Co-crystals. InDrug Formulation Design 2023 Mar 28. IntechOpen.
26. World Health Organization. Emergency Preparedness and Response: Drug Stability Testing. https://www.who.int
27. Koldankaya T, Mert S. Extending the Shelf Life of Doxorubicin Loaded PLGA Nanoparticles with Cryoprotectants. ChemistrySelect. 2024 Nov 4;9(41):e202401759.
28. Bariklana MN, Takayasa TI, Azizah S. IMPLEMENTATION OF EXPIRATION LABELIZATION OF HOUSEHOLD INDUSTRIAL FOOD PRODUCTS (P-IRT). GEMA PUBLICA.;8(2):91-101.
29. Hägglöf I, Holmgren Å. Regulatory affairs. Drug Discovery and Development. Technology Transition. 2012 Jul 20:285-301.

30. Gupta V, Jain A, Shankar MB, Sharma RK. Shelf life of ayurvedic dosage forms in regulatory perspectives. International Journal of Advanced Ayurveda. 2017 May 30;6:360-9.
31. Valavan R, Cesar A. Current status of expiry of homeopathic medicines in Brazil, Germany, India and the United States: a critical review. Homeopathy. 2019 Nov;108(04):232-9.
32. R., D., TIWARI., Guarav, Sanjay, Mahalpure., Poornima, Gulati. The Indian Pharmacopoeia Commission: Challenges, Compliance of Pharmaceutical Industries. Advanced Pharmaceutical Bulletin, (2024). doi: 10.34172/apb.43313.
33. Goyal P, Goyal N, Singh P, Mittal N, Jindal N, Kaur K. Pharmaceutical drugs expiry date tracking: A visionary approach. Concurrency and Computation: Practice and Experience. 2022 Dec 25;34(28):e7358.
34. Sribhavani, KR. (2024). A Brief Review on Drug Regulatory Affairs. Available from: 10.37191/mapsci-2582-4333-6(2)-155
35. Lennard A, Zimmermann B, Clenet D, Molony M, Tami C, Aviles CO, Moran A, Pue-Gilchrist P. Stability Modeling Methodologies to Enable Earlier Patient Access. Journal of Pharmaceutical Sciences. 2024 Sep 27.
36. Arana C, Ji J, Krug E, Liu J, McCaig L, Rozaieski B, Santos C, Sloan J, Charles AM, Wiegeshoff F. Industry Perspective on Temperature Cycling Studies to Meet Regulatory Temperature Excursion Support Requirements: Survey Outcome and Recommendations. Journal of Pharmaceutical Sciences. 2023 Sep 27.
37. Khan MS, Akhtar N. Regulation of stability studies to enhance the efficiency of drug registrations to regulatory authorities. Archives of Pharmacy Practice. 2015;6(3-2015):48-57.
38. Leggett M, Leland J, Kellar K, Epp B. Formulation of microbial biocontrol agents–an industrial perspective. Canadian Journal of Plant Pathology. 2011 Apr 11;33(2):101-7.
39. Ghaeli P. Drugs Expiration Date Dilemma!. Journal of Pharmaceutical Care. 2014:1-2.
40. Grimm W. Extension of the International Conference on Harmonization Tripartite Guideline for Stability Testing of New Drug Substances and Products to countries of climatic zones III and IV. Drug development and industrial pharmacy. 1998 Jan 1;24(4):313-25.
41. Lale S, Kendre A, Gandhi M, Dani S. Role of drug regulatory affairs in Pharma Industry. World Journal of Pharmaceutical Research SJIF. 2015 Mar 27;4(6):615-25.

42. Thomson CM, Savji T. Standards of practice, professional judgment, and scientific evidence to establish and extend a beyond-use date. International Journal of Pharmaceutical Compounding. 2014 Nov 1;18(6):456-60.
43. Swaroop AP, Varun D. A glimpse on expiry date of pharmaceutical dosage forms. PHARMANEST An Int J Adv Pharm Sci. 2011 Sep;2(5-6):423-33.
44. Najlae A, Abdelouahid L, Abdelfettah S. Replenishment triggered by product to eliminate the expiry problem. In2016 3rd International Conference on Logistics Operations Management (GOL) 2016 May 23 (pp. 1-7). IEEE.
45. Thomson CM, Savji T. Standards of practice, professional judgment, and scientific evidence to establish and extend a beyond-use date. International Journal of Pharmaceutical Compounding. 2014 Nov 1;18(6):456-60.
46. Shi J, Chen X, Hu H, Ung CO. Application of implementation science framework to develop and adopt regulatory science in different national regulatory authorities. Frontiers in Public Health. 2023 May 4;11:1172557.
47. Deeksha KS, Balamuralidhara V, Gowthami KR, Thoyajaksha V, Thanush D. India's Regulatory Frames for Adoption of Repurposed Drugs as Covid-19 Treatment: A Recent Study Approach.
48. Mehrotra N, Manchikanti P. Post-trial access to investigational drugs in India: addressing challenges in the regulatory framework. Medical Law Review. 2024 Feb 1;32(1):20-41.
49. Zilker M. *The stability of finished pharmaceutical products and drug substances beyond their labeled expiry dates* (Doctoral dissertation, Universität Würzburg).
50. Sribhavani, KR. A Brief Review on Drug Regulatory Affairs. (2024). doi: 10.37191/mapsci-2582-4333-6(2)-155
51. Pankhuri, Goyal., Nupur, Goyal., Pavneet, Singh., Nischay, Mittal., Neeru, Jindal., Kanwarpreet, Kaur. Pharmaceutical drugs expiry date tracking: A visionary approach. Concurrency and Computation: Practice and Experience, (2022).;34(28) doi: 10.1002/cpe.7358
52. Sheth UK. Regulatory milieu in India. Clinical Pharmacology & Therapeutics. 1976 May;19(5part2):704-9.
53. Brahmachari B, Fernandes M, Bhatt A. Pharmacovigilance for clinical trials in India: Current practice and areas for reform. Perspectives in Clinical Research. 2011 Apr 1;2(2):49-53.
54. Yadav AK, Yadav A, Yadav M, Akhlak M, Mishra S, Rai JK. A review on drug stability. International Journal of Science and Research Archive. 2023;9(1):474-85.

55. Diaz DA, Lynch M, McMahon M, Oblessuc R, Colgan ST. Science and risked-based stability testing strategies—a test case on the global implementation and regulatory reception. The AAPS Journal. 2020 Nov;22:1-1.
56. Rignall A. ICHQ1A (R2) stability testing of new drug substance and product and ICHQ1C stability testing of new dosage forms. ICH quality guidelines: an implementation guide. 2017 Sep 27:3-44.
57. Sahu A, Srivastava N, Jena D, Singh A, Kumar S, Chauhan I. Important Regulatory Guidelines on Natural Products. Current Traditional Medicine. 2024 Dec 1;10(6):152-72.
58. Rampurawala M, Shah C, Upadhyay U. Pharmacovigilance: New Perspective for Drug Safety & Monitoring.
59. MEHRA R, SHARMA MK. Investigation on Critical Indicators of Sustainability in Healthcare. Available at SSRN 4866265.
60. Pathak R, Sharma H, Sachan N, Chandra P. Pharma Marketing in India: Prospects and Challenges. Pharma Marketing and Pharmacoeconomics. 2024 Dec 6:295-329.
61. Agarwal DS, Chairman DT. Central drugs standard control organization . 2017
62. Seth SD, Singh S, Maulik M. Indian Regulatory Framework. InGlobal Clinical Trials 2011 Jan 1 (pp. 89-118). Academic Press.
63. Basha SC, Babu KR, Madhu M, Kumar YP, Gopinath C. Recycling of drugs from expired drug products: comprehensive review. Journal of Global Trends in Pharmaceutical Sciences. 2015;6(2):2596-9.
64. Iserson KV. Should We Use Expired Drugs When Necessary?. The Journal of Emergency Medicine. 2021 May 1;60(5):669-73.